| Document Date: 2014-12-04 16:10:34
Open Document File Size: 575,98 KBShare Result on Facebook
Company Chronic Lymphocytic Leukemia Patient Advocacy Group / Rai / Provincial Advisory Group / / Currency USD / / IndustryTerm patient advocacy / health care services / pharmaceutical manufacturers / treatment of patients with chronic lymphocytic leukemia / / MedicalCondition fever / tumour lysis syndrome / Fatigue / frequently occurring disease / progressive multifocal leukoencephalopathy / opportunistic infections / Disease / diarrhea / infection / Chronic Lymphocytic Leukemia / Mantle Cell Lymphoma / cough / illness / Significant fatigue / Neutropenia / nausea / tumour / previously untreated chronic lymphocytic leukemia / / Organization pCODR Expert Review Committee / Leukemia & Lymphoma Society of Canada / All / / Position investigator / / Product 2mg / cyclophosphamide / /
SocialTag |
considerably higher than the manufacturer’s estimates. pERC agreed that the EGP’s re-analysis estimates were more reliable than those provided by the submitter and concluded that ofatumumab + chlorambucil is not co